<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003249</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02265</org_study_id>
    <secondary_id>UCCRC-9019</secondary_id>
    <secondary_id>NCI-T97-0086</secondary_id>
    <secondary_id>CDR0000066129</secondary_id>
    <nct_id>NCT00003249</nct_id>
  </id_info>
  <brief_title>Carboxyamidotriazole and Ketoconazole in Treating Patients With Advanced Cancers</brief_title>
  <official_title>A Phase I Investigation of Carboxyamido-triazole (CAI) Modulated by Ketoconozole In Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of carboxyamidotriazole and ketoconazole in treating&#xD;
      patients with advanced cancers. Drugs used in chemotherapy use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. Combining more than one drug may kill more&#xD;
      tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of carboxyamidotriazole (CAI) in combination with&#xD;
      ketoconazole in patients with advanced malignancies.&#xD;
&#xD;
      II. Evaluate the toxic effects, safety, and efficacy of CAI in combination with ketoconazole.&#xD;
&#xD;
      III. Determine the modulatory effects of ketoconazole on the pharmacokinetic profile of CAI.&#xD;
&#xD;
      IV. Determine a pharmacodynamic model for CAI and ketoconazole with respect to potential&#xD;
      gastrointestinal, hematologic, and neurotoxicities.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive oral carboxyamidotriazole (CAI) as a test dose on day 1. Patients receive&#xD;
      oral ketoconazole on day 7, followed by CAI plus ketoconazole on day 8. CAI and ketoconazole&#xD;
      are administered in combination on day 1 and days 3-28 of the first course. Ketoconazole is&#xD;
      administered alone on day 2 of the first course. Subsequent courses begin at 28 day intervals&#xD;
      in the absence of disease progression or unacceptable toxic effects. Cohorts of 3 patients&#xD;
      are evaluated at each dose level prior to dose escalation. If one of three patients within a&#xD;
      cohort experiences dose limiting toxicity (DLT), that dose level is expanded to incorporate&#xD;
      six patients. If two or more patients experience DLT, the next lower dose is declared to be&#xD;
      the maximum tolerated dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1998</start_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral carboxyamidotriazole (CAI) as a test dose on day 1. Patients receive oral ketoconazole on day 7, followed by CAI plus ketoconazole on day 8. CAI and ketoconazole are administered in combination on day 1 and days 3-28 of the first course. Ketoconazole is administered alone on day 2 of the first course. Subsequent courses begin at 28 day intervals in the absence of disease progression or unacceptable toxic effects. Cohorts of 3 patients are evaluated at each dose level prior to dose escalation. If one of three patients within a cohort experiences dose limiting toxicity (DLT), that dose level is expanded to incorporate six patients. If two or more patients experience DLT, the next lower dose is declared to be the maximum tolerated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboxyamidotriazole</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically proven refractory or recurrent nonhematologic&#xD;
             malignancies&#xD;
&#xD;
          -  Measurable or evaluable disease by radiographic or clinical examination&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Age: 18 and over&#xD;
&#xD;
          -  Performance Status: Karnofsky 70-100%&#xD;
&#xD;
          -  Absolute neutrophil count at least 2,000/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Albumin at least 3 g/dL&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  No concurrent neurotoxicities greater than grade 1 from previous chemotherapy&#xD;
&#xD;
          -  No concurrent neuropathy greater than grade 1&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Effective contraceptive method must be used by fertile patients during and up to 2&#xD;
             months after study&#xD;
&#xD;
          -  No serious uncontrolled medical illness&#xD;
&#xD;
          -  No history of active inflammatory bowel disease, ileus, or other chronic malabsorption&#xD;
             syndromes&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No concurrent isoniazid&#xD;
&#xD;
          -  No concurrent rifampin&#xD;
&#xD;
          -  At least 4 weeks since chemotherapy&#xD;
&#xD;
          -  At least 6 weeks since nitrosoureas therapy&#xD;
&#xD;
          -  At least 3 months since suramin therapy&#xD;
&#xD;
          -  No prior carboxyamidotriazole&#xD;
&#xD;
          -  No concurrent steroids (except dose required for adrenal insufficiency)&#xD;
&#xD;
          -  No concurrent tamoxifen&#xD;
&#xD;
          -  No prior radiotherapy within 4 weeks of study&#xD;
&#xD;
          -  No prior total gastrectomy or total ileocolectomy&#xD;
&#xD;
          -  No concurrent therapy with H2 antagonists, barbiturates, calcium channel blockers,&#xD;
             terfenadine, astemizole, cisapride, digitoxin, quinidine, amiodarone, carbamazepine,&#xD;
             imipramine, or antacids&#xD;
&#xD;
          -  No concurrent erythromycin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J. Ratain, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2004</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Carboxyamido-triazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

